In each of Verrica’s trials—known as CAMP-1 and CAMP-2 (Cantharidin Application in Molluscum Patients)—a clinically and statistically significant proportion of patients treated with VP-102 showed ...
Zacks Investment Research on MSN
How much upside is left in Verrica Pharmaceuticals (VRCA)? Wall Street analysts think 97.11%
Verrica Pharmaceuticals Inc. (VRCA) closed the last trading session at $7.95, gaining 0.3% over the past four weeks, but ...
On Wednesday, dermatology drug developer Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) released preliminary results from Part 2 of its Phase 2 trial of VP-315 for basal cell carcinoma. The Phase 2 trial ...
Verrica Pharmaceuticals VRCA is preparing to release its quarterly earnings on Tuesday, 2025-08-12. Here's a brief overview of what investors should keep in mind before the announcement. Analysts ...
As of August 2, 2023, the average one-year price target for Verrica Pharmaceuticals is 12.58. The forecasts range from a low of 10.10 to a high of $15.75. The average price target represents an ...
Shares of Verrica Pharmaceuticals Inc. (VRCA) have been struggling lately and have lost 15.3% over the past week. However, a hammer chart pattern was formed in its last trading session, which could ...
SAN FRANCISCO, Oct. 30, 2024 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Verrica Pharmaceuticals Inc. (VRCA) investors that the firm is investigating potential legal claims relating to the ...
We recently compiled a list of the 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers. In this article, we are going to take a look at where Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback